Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment

Revista Brasileira de Psiquiatria

Orestes V. Forlenza¹  Breno S. Diniz¹  Leda L. Talib¹  Marcia Radanovic¹  Monica S. Yassuda¹  Elida B. Ojopi¹  Wagner F. Gattaz¹ 

[1] ,Universidade de São Paulo Department and Institute of Psychiatry, School of Medicine Psychogeriatric Clinic and Laboratory of NeuroscienceSão Paulo SP ,Brazil

关键词: Alzheimer's disease;    Cognition disorders;    Critical pathways;    Biological indicators;    Neurobehavioral manifestations;    Doença de Alzheimer;    Transtornos cognitivos;    Procedimentos clínicos;    Indicadores biológicos;    Manisfestações neurocomportamentais;   

DOI  :  10.1590/S1516-44462010005000002

来源: SciELO

【 摘 要 】

OBJECTIVE: To identify predictors of the progression from pre-dementia stages of cognitive impairment in Alzheimer's disease is relevant to clinical management and to substantiate the decision of prescribing antidementia drugs. METHOD: Longitudinal study of a cohort of elderly adults with amnestic mild cognitive impairment and healthy controls, carried out to estimate the risk and characterize predictors of the progression to Alzheimer's disease. RESULTS: Patients with amnestic mild cognitive impairment had a higher risk to develop Alzheimer's disease during follow-up (odds ratio = 4.5, CI95% [1.3-13.6], p = 0.010). At baseline, older age, lower scores on memory tests and presence of the APOE*4 allele predicted the progression from amnestic mild cognitive impairment to Alzheimer's disease. In a sub sample of amnestic mild cognitive impairment patients, those who progressed to Alzheimer's disease had lower cerebrospinal fluid concentrations of amyloid-beta peptide (Aβ42, p = 0.020) and higher concentrations of total TAU (p = 0.030) and phosphorylated TAU (p = 0.010), as compared to non-converters. DISCUSSION: This is the first Brazilian study to report cerebrospinal fluid biomarkers in the prediction of the conversion from MCI to Alzheimer's disease. Our data are in accordance with those reported in other settings. The measurement of cerebrospinal fluid total-TAU, phospho-TAU and Aβ42 may help identify patients with mild cognitive impairment at higher risk for developing Alzheimer's disease.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License